Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of lopinavir/ritonavir superboosting in HIV and tuberculosis co-infected infants and young children
PACTR201302000426554Recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Dec 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lopinavir, ritonavir and rifampicin in human immunodeficiency virus infection (HIV) and Tuberculosis (TB) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Primary pharmacokinetic endpoint. Started Dec 2012; status: recruiting.
02
Drugs
lopinavirritonavirrifampicin
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201302000426554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201302000426554.